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Increased reticulated platelets in dialysis patients
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Increased reticulated platelets in dialysis patients. The purpose of this
study was to measure the percent reticulated platelets and platelet counts
in patients on chronic hemodialysis, peritoneal dialysis and normal
volunteers. The relationship between the percent reticulated platelets and
the platelet count can then be used to determine the rate of platelet
turnover. Platelet rich plasma was obtained, platelets were fixed and
incubated with thiazole orange and analyzed for the percent reticulated
platelets by flow cytometry. Normal controls had a mean of 2.77 0.17%
reticulated platelets while peritoneal dialysis patients had a mean percent
reticulated platelets of 6.92 0.68 (P < 0.00001). Chronic hemodialysis
patients had a mean percent reticulated platelets of 8.21 0.36 (P <
0.00001 vs. normal controls and P = 0.05 vs. peritoneal dialysis patients).
Platelet counts did not differ significantly among the three groups. The
identity of reticulated platelets was confirmed in experiments measuring
platelet specific glycoproteins, experiments using RNase, and in mixing
experiments with normal and uremic platelets and plasma. We conclude
that dialysis patients have a marked increase in circulating reticulated
platelets compared to normal controls, indicating accelerated platelet
turnover. Increased platelet activation and turnover may contribute to the
qualitative platelet dysfunction observed in dialysis patients.
It has been recognized since at least 1907 that a bleeding
diathesis is a major cause of morbidity and mortality in patients
with uremia [1]. Clinical bleeding in patients with uremia is due to
an acquired qualitative platelet defect and has best been corre-
lated with a prolonged bleeding time [2, 3]. However, at present
there is no single unifying pathogenetic mechanism to explain the
acquired platelet dysfunction of uremia. Numerous studies have
also failed to determine a consistent single intrinsic defect in
platelet dysfunction in uremia.
Studies of acquired platelet dysfunction in patients with end-
stage renal disease are also complicated by the potentially con-
flicting effects of dialysis on platelet dysfunction. Although some
investigators have found that both hemodialysis and peritoneal
dialysis partially improved the hemostatic abnormality of uremia
[4—11], both forms of dialysis can potentially produce adverse
effects on hemostasis. Peritoneal dialysis has been reported to
cause platelet hyper-reactivity which may be related in some cases
to the development of hypoalbuminemia [10]. Hemodialysis is
frequently accompanied by transient platelet activation due to
interactions of platelets with both dialyzer membranes [12—191
and the vascular access itself [20, 21]. Several studies have
suggested that platelet activation during hemodialysis may be
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associated with a transient worsening of platelet dysfunction
[22—26]. A repetitive activation of platelets that is caused by the
dialysis procedure may induce platelet refractoriness to further
stimulation, thereby contributing to the clinical bleeding some-
times observed temporally related to the dialysis procedure.
While there are conflicting studies examining platelet function
in dialysis patients, there are no studies examining platelet
survival in this patient population. This is primarily due to the
technical difficulties involved in measuring the survival of radio-
labeled platelets in patients who are undergoing intermittent
extracorporeal procedures. Recently a new approach to measur-
ing in vivo platelet turnover has been developed that utilizes the
nucleic acid content of platelets to identify reticulated platelets
that have been recently released into the circulation [27—29].
Reticulated platelets, similar to reticulated erythrocytes, lose their
RNA content in the process of aging and senescence. Because
reticulated platelets are detectable in the circulation for only 24
hours [30, 31], they are an excellent measure of platelet produc-
tion and turnover.
We measured the percentage of reticulated platelets in patients
with end-stage renal disease on hemodialysis or peritoneal dialysis
compared to normal controls and have demonstrated increased
reticulated platelet levels in dialysis patients despite normal
platelet counts, suggesting increased platelet turnover compared
to controls. We have further validated these measurements by
demonstrating platelet specific glycoproteins on reticulated plate-
lets to confirm that these cells are platelets and by using RNase to
confirm the specificity of platelet reticulation.
Methods
Patient populations
Twenty-eight patients on chronic maintenance hemodialysis, 22
patients with end-stage renal disease on chronic peritoneal dial-
ysis, as well as 20 normal volunteers were chosen at random. No
patients or controls were on aspirin, NSATDS or other medica-
tions known to interfere with platelet function. Seven of the 22
patients on chronic peritoneal dialysis and 10 of the 28 patients on
chronic maintenance hemodialysis were diabetic. Of the chronic
hemodialysis patients, 12 were being dialyzed with cellulosic
membranes and sixteen with polysulfone membranes. All patients
were on a hemodialysis reuse program using 1% formaldehyde
incubated at 40°C for at least 24 hours as a sterilant. Bleach was
not used in the processing of these dialyzers. Anticoagulation was
maintained using heparin at an initial bolus of 100 UIg with
additional doses if activated clotting times were less than 1.5 times
predialysis values.
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Fig. 1. Identification of platelet reticulation with flow cytometly. The analysis of data from a normal control subject (A) and a hemodialysis patient (B)
are illustrated. In each panel the horizontal axis is forward angle light scatter (a measure of particle size) and the vertical axis is thiazole orange
fluorescence (a measure of RNA).
Measurement of reticulated platelets
Reticulated platelets were measured according to previously
described methods. Briefly, whole blood was drawn into EDTA
vacutainer tubes, predialysis and prior to heparinization in chronic
hemodialysis patients, or at the time of routine monthly visits in
chronic peritoneal dialysis patients. Platelet-rich plasma was
prepared by centrifugation of blood anticoagulated with EDTA.
The platelets were then washed, fixed in 1% paraformaldehyde,
washed again, and resuspended at 107/ml in Tyrode's buffer
containing 10 mmol/liter EDTA, One hundred microliters of this
suspension was mixed with 900 microliters of thiazole orange
solution (Becton-Dickinson, San Jose, CA, USA) and incubated
at room temperature for one hour. The samples were then
analyzed on the flow cytometer. In some experiments washed
platelets were also labeled with phycoerythrin conjugated mono-
clonal anti-GPIIb/IIIa or GPIb (AMAC Inc., Westbrook, ME,
USA),
Flow cytometric data analysis
Analysis of the samples was carried out using a Becton-
Dickinson FACScan flow cytometer. Analysis of thiazole orange
positivity was done by measuring both forward light scatter and
green (540 nm) fluorescence using logarithmic amplification. A
plot of forward light scatter versus fluorescence was generated,
showing the expected positive correlation between forward light
scatter, which is a measure of particle size and fluorescence. Large
platelets containing more nucleic acid were assumed to represent
reticulated platelets. To define the frequency of reticulated plate-
lets, a standardized bitmap was created using a line with the same
slope of green fluorescence as the platelet cluster set (Fig. 1).
Platelets in the bitmap above this line were considered reticulated
platelets (such as expressing more thiazole orange positivity).
Treatment of platelets with RNase
Samples of washed platelets with high levels of reticulated
platelets were fixed in 1% paraformaldehyde and then treated
with 1 mg/ml RNase (Sigma Chemical, St. Louis, MO, USA) for
30 minutes at 37°C. The treated platelets were then washed and
labeled with thiazole orange, as described above.
Statistics
Comparisons of platelet count and percent of reticulated
platelets between normal controls, peritoneal dialysis patients and
hemodialysis patients were made using an F test to determine
variance followed by a two-tailed t-test. Comparisons of relation-
ship of the platelet count to the percent of reticulated platelets
within each group was made using linear regression analysis.
Comparisons of the percent of reticulated platelets before and
after RNase treatment were made using a paired t-test.
Results
Measurement of reticulated platelets in normal human volunteers,
peritoneal dialysis patients and hemodialysis patients
Figure 2 illustrates the results of studies of 20 normal volun-
teers in whom we measured both the platelet count and the
percentage of reticulated platelets. The mean platelet count was
248,000 9,100/pA (range 192,000 to 327,000/1id). The mean
percent reticulated platelets was 2.77 0.17 (range 1.39 to
4.48%). Figure 3 represents results of studies of 22 patients on
chronic peritoneal dialysis. The mean platelet count was
283,000 17,000/,.d (range 120,000 to 43O,000/pJ), which was not
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Fig. 3. Percent reticulated platelets and platelet counts in chronic peritoneal 0.000
dialysis patients.
statistically significantly different than normal controls. In con-
trast, the mean percent reticulated platelets was 6.96 0.68
(range 1.98 to 11.67), which was significantly different (P <
0.00001) compared to normal controls. Figure 4 illustrates the
results of studies in 28 patients on chronic maintenance hemodi-
alysis. In this patient group the mean platelet count was 278,000
23,000/pA (range 94,000 to 703,000/pA), which was not statistically
significantly different from either peritoneal dialysis patients or
normal volunteers. The mean percent of reticulated platelets was
8.21 0.36 (range 4.97 to 10.36%), which was significantly
different from normal controls (P < 0.00001) and also significantly
different from peritoneal dialysis patients (P = 0.05).
To determine if there was a relationship between the platelet
count and the percent of reticulated platelets for chronic hemo-
dialysis patients, peritoneal dialysis patients and normal controls,
linear regression analysis was performed for each group. In each
case there was no significant relationship between the platelet
count and the percent reticulated platelets. The R value for the
relationship between the platelet count and the percent reticu-
lated platelet was 0.195 for chronic hemodialysis patients, 0.234
for chronic peritoneal dialysis patients and 0.140 for normal
controls.
Because previous studies have indicated a relationship between
diabetes mellitus and platelet hyperreactivity, we examined the
relationship between the presence or absence of diabetes mellitus
and the percent reticulated platelets in both chronic peritoneal
dialysis patients and chronic hemodialysis patients (Fig. 5). The
percent reticulated platelets did not differ in the chronic hemodi-
alysis population between diabetics (8.32 0.70) and non-
diabetics (8.15 0.41). Similarly, there were no differences in the
percent reticulated platelets between diabetics (6.77 0.96) and
non-diabetics (7.05 0.91) among patients on chronic peritoneal
dialysis. Platelet counts also did not differ between diabetics and
non-diabetics either in the chronic hemodialysis patients (288,000
33,000 .t/liter vs. 260,000 27,000 pr/liter) or in the patients on
chronic peritoneal dialysis (280,000 3100 p/liter vs. 285,000
22,000 p/liter). Thus, the presence or absence of diabetes mellitus
does not account for the differences in the percent reticulated
platelets between patients on chronic dialysis therapy and normal
controls.
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Fig. 2. Percent reticulated platelets and platelet counts in normal subjects. % Reticulated platelets
Fig. 4. Percent reticulated platelets and platelet counts in chronic hemodi-
alysis patients.
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Fig. 5. Percent reticulated platelets in diabetic (LI) and non-diabetic ()
dialysis patients.
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Measurement of platelet specific glycoproteins on reticulated
platelets
To confirm the identity of reticulated platelets as RNA bearing
platelets, platelets were simultaneously stained with thiazole
orange and phycoerythrin conjugated monoclonal antibodies to
glycoprotein lb or glycoprotein lib-Illa. In all cases, both reticu-
lated and nonreticulated platelets exhibited greater than 94%
positivity for both glycoprotein lb and glycoprotein Jib-lila
staining (data not shown). This experiment confirms the identity
of flow cytometrically labeled reticulated platelets as platelets
because of their expression of platelet-specific cell surface pro-
teins.
Identification of reticulated platelets as RNA containing platelets
To demonstrate that thiazole orange positivity in reticulated
platelets was due to the presence of RNA, samples were incu-
bated with RNase. The percent reticulated platelets were then
determined in the same samples with or without RNase (Fig. 6).
In all cases there was a significant reduction in percent of thiazole
orange positive reticulated platelets after the addition of RNase.
As we and others have previously noted, the use of RNase before
labeling reticulated platelets does not completely abolish thiazole
orange positive staining in the platelet preparation. The residual
RNase resistant labeling may be due to ribosomal RNA or
possibly be due to other platelet components that take up thiazole
orange dye.
Mixing experiments with normal and uremic platelets and plasma
Mixing experiments were performed to confirm that chronic
renal failure is not associated with a plasma factor or retained
uremic toxin that affects the thiazole orange positive staining of
platelets. Plasma from patients on chronic dialysis was mixed with
normal platelets, while plasma from normal volunteers was also
mixed with platelets from chronic hemodialysis patients and the
percent of thiazole orange positive staining was determined (Fig.
7). Platelets from chronic hemodialysis patients expressed a
higher level of thiazole orange positivity whether they were
assayed in normal plasma (8.5 0.9%) or in uremic plasma (8.6
0.6%) when compared to platelets from normal volunteers mixed
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either with normal plasma (4.3 0.5%) or uremic plasma (3.9
0.4%). These experiments confirm that the increase in thiazcle
orange positive reticulated platelets seen in dialysis patients is
indeed due to increased levels of platelet RNA and not due to any
interfering substance from uremic plasma.
Discussion
In this study we have demonstrated that patients with end-stage
renal disease who are treated with either chronic peritoneal
dialysis or hemodialysis have a markedly increased percentage of
circulating reticulated platelets compared to normal controls.
Since the platelet counts were similar among the three groups,
these results strongly suggest that both peritoneal dialysis and
hemodialysis patients have markedly increased in vivo platelet
turnover compared to normal controls.
Although there have been many studies of platelet function in
patients with renal disease, there are, to our knowledge, no
previous studies examining platelet turnover. Previous techniques
to quantify platelet production and turnover were limited to bone
marrow examination, mean platelet volume and platelet radio
labeling techniques. Bone marrow aspiration is subjective in its
interpretation and may vary between aspirates in the same
subject. The mean platelet volume is a parameter that is also
subject to a number of technical variables, including type of
anticoagulation, time of measurement following venipuncture,
and the type of technology used to determine the platelet size
[32]. Platelet radiolabeling techniques arc difficult to standardize
and are also subject to technical difficulties when patients are
undergoing intermittent extracorporeal treatments. Recent stud-
ies have also emphasized that radiolabeling techniques can have
problems related both to in vivo platelet compartmentalization
(especially if platelets are injured or activated in the collection or
radionuclidc labeling process 133, 34]) as well as elution of
radionuclide from platelets in vivo [35].
Karpatkin suggested more than two decades ago that platelets,
like erythrocytes, decrease in size, reduce their rate of protein
synthesis and decrease their RNA content as they age [36]. Since
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Fig. 6. Effect of RNase on measurement of platelet reticulation. Symbols Normal platelets U remic platelets
are: (E2) samples without RNase; (LI) samples with RNase. Results are
from two experiments with four healthy subjects and seven hemodialysis Fig. 7. Platelet and plasma mccing expenments. Percent reticulated plate-
patients. P < 0.05 versus samples without RNase. lets were measured in samples in which either normal () or uremic (LI)
platelets were incubated with normal or uremic plasma. N = 3 experi-
ments. p < 0.05 normal versus uremic platelets.
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that time, considerable evidence has accumulated that the nucleic
acid content of platelets can be used to identify those platelets
that have recently been released into the circulation. Kienast and
Schmitz first proposed using the dye thiazole orange and flow
cytometry to measure individual platelet nucleic acid content [37].
Thiazole orange is an ideal dye for measuring intracellular nucleic
acid content and has become the standard for the flow cytometric
analysis of reticulated erythrocytes. Thiazole orange enters living
cells without any pretreatment, and displays a very large increase
in fluorescence emission on binding to RNA and DNA [381.
Using a mouse model of in vivo biotinylation we have recently
demonstrated that reticulated platelets are indeed the youngest
platelets in circulation, circulating for an estimated 1.8 days prior
to losing RNA [30]. Dale and colleagues have also recently used
an in vivo biotinylation technique in a dog model [31] to demon-
strate that thiazole orange positive platelets are less than 24 hours
old. The measurement of circulating reticulated platelets has been
utilized to evaluate platelet turnover in thrombocytopenic disor-
ders [28, 29]. The use of reticulated platelets can detect consump-
tive platelet disorders with a positive predictive value of 96% and
a negative predictive value of 100% [29]. In patients undergoing
stem-cell transplantation a rise in the percent of reticulated
platelets precedes the rise in the platelet count [29], analogous to
the increase in reticulated erythrocytes seen before an increase in
the red cell mass during erythropoiesis [39—4 1]. Thus, there are
considerable data to suggest that reticulated platelets can be used
as a non-invasive, accurate measure of platelet turnover, analo-
gous to the use of reticulated erythrocytes to measure erythrocyte
turnover.
In this study, patients on chronic maintenance hemodialysis had
a higher percentage of circulating reticulated platelets than either
chronic peritoneal dialysis patients or normal controls. Although
mechanisms involved in platelet activation during transit through
an extracorporeal circulation are complex and currently not well
understood, there is little doubt that platelets are profoundly
affected by exposure to foreign surfaces during transit through the
dialyzer. Changes in blood rheology, shear force, temperature and
the pattern of flow over the dialyzer surface may all potentially
affect platelet activation during hemodialysis [12—26]. In contrast
to chronic hemodialysis, the mechanisms of increased platelet
turnover in patients on chronic peritoneal dialysis compared to
normal levels is less clear. Several earlier studies have suggested
that peritoneal dialysis is associated with platelet hyperreactivity,
possibly in conjunction with the hypoalmbuminemia that fre-
quently complicates peritoneal dialysis [10]. Alternatively, uremia
itself may be associated with increased platelet turnover.
In summary, we have demonstrated that patients on chronic
hemodialysis and peritoneal dialysis have a markedly increased
level of circulating reticulated platelets compared to normal
controls. These results strongly suggest that platelet turnover in
patients on dialysis are two- to threefold higher than normal
controls. Also, platelet turnover in hemodialysis patients was
higher than in peritoneal dialysis patients, suggesting that repet-
itive platelet activation during extracorporeal circulation may
contribute to platelet turnover. These results would support the
hypothesis that patients with renal failure on dialysis actually exist
in a state of chronic platelet activation that leads to increased
platelet turnover. Repetitive platelet activation related to both
uremia and the dialysis procedure leads to a state where platelets
are refractory to further activation [42]. An increased rate of
platelet turnover may contribute to the acquired platelet defect
associated with renal failure.
Reprint requests to Jonathan Himmelfarb, MD., Division of Nephrology,
Maine Medical Center, 22 Bramhall Street, Portland, Maine 04102, USA.
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